DaVita Inc.

DaVita Inc. Earnings Recaps

DVA Health Care 4 recaps
Next earnings: February 1, 2027 (estimated) · full calendar
Q3 2026 Nov 3, 2026

DaVita shares fell 3.0% after earnings, with higher-than-forecast technology investment in U.S. dialysis weighing on full-year financial performance. The transcript also points to limited near-term financial contribution from expanded HD: management expects no material net impact on adjusted operating income in 2026 or 2027.

Key takeaways
  • Q3 adjusted operating income was **$561 million** and adjusted EPS was **$3.82**.
  • Technology investment was higher than forecast heading into the year and is a drag on full-year performance; management expects its growth to decelerate going forward.
  • IKC was above plan in Q3, and the company said it was on track to outperform its original full-year guidance.
  • Expanded HD pilots covered **150 centers** and more than **10,000 patients**; adoption among clinically eligible pilot patients exceeded **90%**. National rollout was due to begin the following week, with most eligible patients expected to transition in November.
  • Management expects expanded HD’s positive impact from lower mortality and higher volume growth to begin in the **second half of 2028**; it cited a goal of returning to **2% or greater volume growth by 2029**.
Q2 2026 Aug 6, 2026

Shares dropped 19.3% following DaVita’s Q2 report as investors reacted negatively to margin compression and a cautious outlook driven by lower sequential revenue per treatment and expected headwinds from declining ACA enrollment and phosphate binder reimbursement.

Key takeaways
  • Volume growth accelerated year-over-year, slightly surpassing expectations due to improvements in patient mortality.
  • Revenue per treatment declined sequentially, negatively impacted by a lower commercial mix from ACA enrollment declines and reduced contribution from phosphate binders.
  • Gross margin pressure emerged, partly reflecting the transition of phosphate binders into the Medicare dialysis bundle and reimbursement complexities.
  • Management highlighted support for upcoming CMS ESRD payment rule changes but acknowledged proposed Medicare base rate updates will likely trail industry cost inflation.
  • New dialysis therapies (expanded HD with medium cutoff dialyzers) were positioned as a future growth and clinical advancement opportunity but have yet to offset current financial headwinds.
Q1 2026 May 7, 2026

DaVita's stock surged 25.8% as the company delivered better-than-expected volume growth, raised full-year guidance, and demonstrated early traction from technology investments supporting operational efficiency and clinical outcomes.

Key takeaways
  • Treatment volume came in slightly ahead of forecast, driven by better-than-expected mortality trends and patient transfers from Fresenius clinic closures.
  • Raised full-year volume growth expectations to 25-50 basis points, attributing about half the gain to Fresenius transfers and half to organic improvement.
  • Adjusted operating income of $482 million beat internal forecasts by approximately $50 million, with half due to actual performance and half due to timing benefits.
  • Adjusted EPS guidance was increased to a $14.10–$15.20 range, reflecting higher volume and lower patient care costs.
  • Continued investments in data infrastructure and AI, including deployment of ScheduleHub to optimize scheduling, are positioning the company for operational scale and improved clinical outcomes.
Q3 2025 Oct 30, 2025

DaVita reported a strong third quarter in 2025, achieving adjusted operating income of $517 million and adjusted earnings per share of $2.51, maintaining its trajectory for the full year.

Key takeaways
  • Adjusted operating income and earnings per share were consistent with internal expectations, reaffirming guidance for the year.
  • The company's clinical research division, DaVita Clinical Research, remains a leader in advancing kidney care, conducting over 500 clinical trials and contributing to FDA approvals.
  • Effective management of patient care costs, despite a 1.5% year-over-year decline in U.S. treatment volume, has supported financial stability.
  • Strategic investments in technology infrastructure and AI solutions are expected to enhance patient care and operational efficiency long-term.
  • Full-year adjusted operating income guidance narrowed to $2.035 – $2.135 billion, with earnings per share projected between $10.35 and $11.15.